Posted on 8/29/18
Pfizer's Tafamidis Will Be Standard Of Care For A Not-So-Rare Disease
SummaryDrugs that are shown to improve survival quickly become standard of care.Tafamidis is the only drug known to improve survival in transthyretin-related (TTR) cardiac amyloidosis and . . .
Posted on 8/31/17
Celgene Has Led Bluebird Into A Crowded Field
Two years ago, when Lenti-D and LentiGlobin were still its lead product candidates, I viewed bluebird bio (BLUE) as industry leader in the development of gene . . .
Posted on 8/29/17
Johnson & Johnson's Darzalex Is An Emerging Threat To The Primacy Of Celgene's Revlimid
Last week Genmab A/S (OTCPK:GNMSF), (OTCPK:GMXAY) announced positive topline results for its phase III ALCYONE study, sponsored by Janssen, a division of Johnson & Johnson (JNJ). . . .
Boston
